The goal of this application is to create immunoconjugates that home to the vasculature of solid tumors, coagulate the tumor's blood supply and induce tumor infarction. The key advantage of this approach over direct tumor cell targeting is that the vascular endothelial cells of the tumor are freely accessible through the blood whereas the tumor cells are relatively inaccessible. Also, endothelial cells are normal cells making the outgrowth of resistant mutants unlikely, and are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. The applicant previously established """"""""proof of principle"""""""" by inducing major tumor regressions in mice bearing large solid tumors with immunoconjugates prepared from antibodies that recognize an experimentally-induced tumor endothelial cell marker (MHC Class II). The effectors were ricin A-chain, which kills the tumor endothelial cells and induces platelet adhesion on the injured vessels, or a genetically engineered form of the coagulation initiating protein tissue factor, which directly induces thrombotic occlusion of the vessels. In this application, the applicant will synthesize vascular targeting agents that recognize the naturally occurring tumor endothelial cell marker, vascular endothelial cell growth factor (VEGF). VEGF is present in the receptors on tumor endothelial cells but not in those on endothelial cells in normal tissues and, hence, non-blocking antibodies to VEGF home selectively to tumor vessels in vivo. Monoclonal antibodies to human VEGF will be raised; their ability to localize to vessels in solid tumors in mice and guinea pigs will be confirmed; toxin-containing immunotoxins and tissue factor-containing """"""""coaguligands"""""""" will be synthesized; and the pharmacokinetics, toxicity and anti-tumor activity of the drugs in murine and guinea pig tumor models will be determined. These studies will pave the way to clinical trials of anti-VEGF vascular targeting agents in patients with solid tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA074951-01
Application #
2372168
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1997-09-30
Project End
1998-05-31
Budget Start
1997-09-30
Budget End
1998-05-31
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Huang, Xianming; Bennett, Mary; Thorpe, Philip E (2004) Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61:1-11
Mason, Ralph P; Constantinescu, Anca; Ran, Sophia et al. (2003) Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. Adv Exp Med Biol 530:197-204
Ran, Sophia; Huang, Xianming; Downes, Amber et al. (2003) Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 5:297-307
Ran, Sophia; Downes, Amber; Thorpe, Philip E (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62:6132-40
Zhang, Wei; Ran, Sophia; Sambade, M et al. (2002) A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5:35-44
Mason, Ralph P; Ran, Sophia; Thorpe, Philip E (2002) Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. J Cell Biochem Suppl 39:45-53
Brekken, R A; Thorpe, P E (2001) Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 21:4221-9
Giatromanolaki, A; Sivridis, E; Athanassou, N et al. (2001) The angiogenic pathway ""vascular endothelial growth factor/flk-1(KDR)-receptor"" in rheumatoid arthritis and osteoarthritis. J Pathol 194:101-8
Gottstein, C; Wels, W; Ober, B et al. (2001) Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. Biotechniques 30:190-4, 196, 198 passim
Brekken, R A; Overholser, J P; Stastny, V A et al. (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117-24

Showing the most recent 10 out of 17 publications